Key result
Early SGLT2i initiation during AHF hospitalization reduces all-cause mortality without increasing adverse events.
1/3 https://e
No takes yet. Share an insight, caveat, or question.
Yoon et al. (2026) conducted an editorial in Acute Heart Failure (n=3,600). SGLT2 inhibitors vs. Standard care or placebo was evaluated on All-cause mortality. Early initiation of SGLT2 inhibitors during hospitalization for acute heart failure significantly reduced all-cause mortality without increasing adverse events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: